Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImThera Medical Inc.

This article was originally published in Start Up

Executive Summary

Although more than 20 million people in the US are affected by obstructive sleep apnea (OSA), the standard of care for the disorder--a continuous positive airway pressure (CPAP) machine applied at bedtime with a nasal or facial mask to keep airways propped open--carries a noncompliance rate of almost 50%. ImThera Medical Inc. is developing a new implantable neurostimulation device that stimulates certain tongue muscles during sleep to open the upper airway and potentially help patients who are unable or unwilling to use CPAP or pursue surgical alternatives.

You may also be interested in...



Sleep Apnea Devices: The Changing Of The Guard

The current specialty-dominated care paradigm for sleep apnea can't scale-up to meet the demands of an enormous and serious chronic disease. New companies help move diagnosis and treatment to the physicians that see patients first.

New Avenues in Neuromodulation

Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."

Apnex Medical Inc.

Apnex Medical is developing a tiny device that it thinks could become an enormous game changer in the bid to better treat obstructive sleep apnea. The technology is similar to a pacemaker in both size and concept. But instead of the heart, the device stimulates the musculature of the upper airway at the base of the tongue - the genioglossus - via the hypoglossal nerve. In obstructive sleep apnea, the muscle doesn't always activate sufficiently, which can lead to a collapsed airway.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel